Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928872 | 0.93 | DRD2 (0.57) | DRD2DRD3SMN1; SMN2 | |
| SCHEMBL2928909 | 0.87 | KDM2B (0.48) | DRD2DRD3KDM4EGAASMN1; SMN2 | |
| SCHEMBL7430034 | 0.86 | DRD2 (0.51) | DRD2DRD3SMN1; SMN2MEN1CYP2C9 | |
| SCHEMBL2926891 | 0.82 | DRD2 (0.51) | DRD2DRD3HTR1AKCNH2KDM4E | |
| SCHEMBL2922399 | 0.81 | TMEM97 (0.45) | KDM4EHTR7SMN1; SMN2CYP2C19 | |
| SCHEMBL2925539 | 0.77 | SMN1; SMN2 (0.48) | KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL2929064 | 0.77 | HTR6 (0.53) | HTR1AKDM4EHTR7SMN1; SMN2KMT2A | |
| SCHEMBL2928035 | 0.74 | DRD2 (0.60) | DRD2DRD3KDM4EGAA | |
| SCHEMBL2927674 | 0.74 | DRD2 (0.60) | DRD2DRD3KDM4EGAA | |
| SCHEMBL9484728 | 0.74 | CYP2C19 (0.49) | DRD2DRD3KCNH2GAAHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41315-E1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) | 2010-05-04 | — | — | US | disclosed |
| US-6924374-B2 | Central nervous system disorders; psychological disorders | A. CARLSSON RESEARCH AB (SE) | 2005-08-02 | — | — | US | disclosed |
| EP-1419773-A2 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | disclosed |
| EP-1240143-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046146-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | DRD2 16/4885DRD3 22/4885HTR1A 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.